Suzhou Zelgen Biopharmaceuticals Co Ltd Market Cap ($3.52 Billion)
Market Cap & Net Worth: Suzhou Zelgen Biopharmaceuticals Co Ltd (688266)
Suzhou Zelgen Biopharmaceuticals Co Ltd market cap. Suzhou Zelgen Biopharmaceuticals Co Ltd (SHG:688266) has a market capitalization of $3.52 Billion (CN¥24.04 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #4315 globally and #628 in its home market, demonstrating a 7.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Suzhou Zelgen Biopharmaceuticals Co Ltd's stock price CN¥90.80 by its total outstanding shares 264708186 (264.71 Million). Also see cash flow conversion of Suzhou Zelgen Biopharmaceuticals Co Ltd for how efficiently the company converts equity into cash flow.
Suzhou Zelgen Biopharmaceuticals Co Ltd Market Cap History (2020–2026)
Suzhou Zelgen Biopharmaceuticals Co Ltd market cap history from 2020 to 2026. Data shows growth from $2.51 Billion to $3.52 Billion (2.94% CAGR). Check 688266 stock price and chart for real-time trading data and today's change.
Suzhou Zelgen Biopharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Suzhou Zelgen Biopharmaceuticals Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.53x
Suzhou Zelgen Biopharmaceuticals Co Ltd's market cap is 4.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.51 Billion | $27.66 Million | -$319.23 Million | 90.59x | N/A |
| 2021 | $2.28 Billion | $190.36 Million | -$451.00 Million | 11.96x | N/A |
| 2022 | $1.62 Billion | $302.31 Million | -$457.33 Million | 5.34x | N/A |
| 2023 | $2.05 Billion | $386.44 Million | -$278.58 Million | 5.31x | N/A |
| 2024 | $2.41 Billion | $532.95 Million | -$137.83 Million | 4.53x | N/A |
Competitor Companies of 688266 by Market Capitalization
Companies near Suzhou Zelgen Biopharmaceuticals Co Ltd in the global market cap rankings as of November 9, 2026. Also see total assets of Suzhou Zelgen Biopharmaceuticals Co Ltd for a full breakdown of the balance sheet.
Key companies related to Suzhou Zelgen Biopharmaceuticals Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Suzhou Zelgen Biopharmaceuticals Co Ltd (2020–2026)
Market capitalization of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2020 to today. Between 2020 and today, Suzhou Zelgen Biopharmaceuticals Co Ltd's market cap moved from $2.51 Billion to $ 3.52 Billion, with a yearly change of 2.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.52 Billion | -2.05% |
| 2025 | CN¥3.59 Billion | +48.77% |
| 2024 | CN¥2.41 Billion | +17.70% |
| 2023 | CN¥2.05 Billion | +26.95% |
| 2022 | CN¥1.62 Billion | -29.08% |
| 2021 | CN¥2.28 Billion | -9.10% |
| 2020 | CN¥2.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Suzhou Zelgen Biopharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.52 Billion USD |
| MoneyControl | $3.52 Billion USD |
| MarketWatch | $3.52 Billion USD |
| marketcap.company | $3.52 Billion USD |
| Reuters | $3.52 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more